Marshall Wace
FULC icon

Marshall Wace’s Fulcrum Therapeutics FULC Stock Holding History

Marshall Wace’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Buy
+1,358,423
New +$8.26M ﹤0.01% 1379
2026
Q1 		– Sell
-102,921
Closed -$1.16M – 3378
2025
Q4 		$1.16M Buy
+102,921
New +$1.05M ﹤0.01% 1854
2024
Q3 		– Sell
-333,161
Closed -$2.07M – 2664
2024
Q2 		$2.07M Buy
333,161
+107,588
+48% +$815K ﹤0.01% 1354
2024
Q1 		$2.13M Sell
225,573
-279,529
-55% -$2.5M ﹤0.01% 1333
2023
Q4 		$3.41M Sell
505,102
-543,544
-52% -$2.41M 0.01% 1043
2023
Q3 		$4.66M Buy
1,048,646
+1,031,246
+5,927% +$4.51M 0.01% 893
2023
Q2 		$57.4K Sell
17,400
-103,600
-86% -$304K ﹤0.01% 2365
2023
Q1 		$345K Buy
121,000
+105,474
+679% +$945K ﹤0.01% 2246
2022
Q4 		$113K Sell
15,526
-4,589
-23% -$29.9K ﹤0.01% 2776
2022
Q3 		$162K Buy
+20,115
New +$144K ﹤0.01% 3127
2022
Q1 		– Sell
-13,513
Closed -$239K – 3562
2021
Q4 		$239K Sell
13,513
-138,176
-91% -$2.74M ﹤0.01% 3103
2021
Q3 		$4.28M Buy
+151,689
New +$2.87M 0.02% 1029

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's FULC Position: Q2 2026 in Review

Marshall Wace opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 1,358,423 shares worth $4.97M. The stake represents ﹤0.01% of the portfolio and ranks #1379 among its holdings. This is a return to the name: Marshall Wace previously reported a position in FULC as recently as Q4 2025.

Marshall Wace first reported a position in FULC in Q3 2021 and has held it in 12 quarters since. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Marshall Wace held 1,358,423 shares of Fulcrum Therapeutics worth $4.97M as of Q2 2026.
  • Fulcrum Therapeutics was a new Marshall Wace position in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1379 holding.
  • Marshall Wace first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.